Asthma and Allergic Diseases Cooperative Research Centers
The purpose of this notice of funding opportunity (NOFO) is to invite applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and translational research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest, including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.
NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement
This NOFO invites applications for investigator-initiated, high-risk multi-center therapeutic clinical trials conducted at one or more clinical centers. A multi-center study is classified as “high risk” if it utilizes either a high-risk intervention or has high operational risk, or both. NOT-DK-20-051 provides an explanation of high-risk versus low-risk studies.
Proposed trials should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK, including trials to address diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders and obesity; and kidney, urologic, and hematologic diseases. Proposed trials are expected to improve understanding, diagnosis, prevention, or treatment of the diseases being studied, and should focus on research questions likely to change clinical practice and/or improve public health.
Multimodal Artificial Intelligence to Accelerate HIV Clinical Care
Novel, data-driven approaches will be necessary to fulfill the Ending the HIV Epidemic in the U.S. (EHE) key strategies to diagnose, prevent, and treat, and respond. The use of transformative technologies in fields such as artificial intelligence (AI) can accelerate scientific discovery, leading to new breakthroughs and innovative strategies for ending the HIV epidemic. Opportunities for using AI in making predictions, real-time monitoring, or to improve decision-making to address HIV prevention, care, and treatment needs abound but have yet to be fully realized. Recent advances in highly flexible, multimodal AI models have generated much interest and discussion about the promise of AI to transform research, clinical care, and public health. This NOFO seeks to leverage these advances by encouraging the use of cutting-edge multimodal AI models to expand our capacity to address the dynamic, complex, and evolving HIV epidemic.
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders
The purpose of this notice of funding opportunity (NOFO) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this NOFO will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders. This NOFO encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.
This NOFO will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).
This NOFO supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme, or program goal, requiring a broadly based, multidisciplinary, and often long-term approach should consider the companion NOFO PAR-25-353